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Abstract: Cerebral sparganosis is a rare parasitic infection of the brain caused by the 
tapeworm Spirometra spp. Surgical removal is the only therapy with documented efficacy. 
We report a case of a patient with a biopsy-confirmed sparganosis, where an initially false 
diagnosis with futile treatment, transient loss to follow up and refusal of suggested surgery 
allowed documenting the migration track of the wandering sparganum through the brain 
parenchyma over 2.5 years by MRI. We treated the patient with a high dose regimen of 
praziquantel since the patient refused a surgical intervention. Following medication, imaging 
signs of active cerebral sparganosis receded, specific anti-sparganum IgG antibody levels 
normalized and clinical symptoms improved, suggesting that the sparganum had been 
eradicated.  
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Dear Sirs, 
A 39-year-old Bangladeshi man was admitted to our hospital with a first generalized epileptic 
seizure. Brain MRI showed multiple ring-enhancing lesions with perifocal edema (A and G, 
February 2008). CSF analysis showed 8 cells/µl and normal protein, glucose and lactate 
levels. Serum and CSF serological tests were negative for a broad range of parasites, fungi 
and bacteria.  
 
The patient was suspected to have neurocysticercosis and was treated with albendazole 
(400mg bi-daily for 30 days). However, follow up MRI showed new, adjacent lesions with 
ring- and tunnel-shaped enhancement; and punctate calcifications in the left parieto-occipital 
area in the CT (B,H and M, December 2009), suggesting that the treatment had been 
ineffective. We therefore performed a brain biopsy (with prior MRI for the localization of the 
sparganum, C and I, February 2010), which revealed a degenerated cyst containing membrane 
shaped structures with multiple foci of calcification. PCR was positive for Spirometra 
erinaceieuropaei, leading to the diagnosis of cerebral sparganosis. 
 
Surgical removal of the parasite is the treatment of choice as standard antihelmintic therapy is 
considered ineffective in sparganosis [1-3]. The repeated MRI indicated that the lesion had 
been wandering again (D and J). An ethylcholine PET showed a defined region with increased 
tracer uptake most likely indicating the current location of the sparganum (N). However, the 
patient refused the recommended stereotactic surgery. We therefore treated the patient with a 
high dose regimen of praziquantel (3 x 25 mg/kg body weight daily) for 7 days combined 
with cimetidine (3 x 400 mg daily) and a high carbohydrate diet to increase plasma levels of 
praziquantel [4]. The treatment was well tolerated. 
 
Follow up MRI 3 months and 11 months later showed drastically improved findings and the 
ethylcholine PET had normalized (E, F, K, L, O and P). Anti-sparganum antibody levels were 
determined from preserved CSF and serum samples by a specific ELISA [5]. Before therapy 
(December 2009), anti-sparganum antibody levels were elevated in the serum (0.29) and in 
the CSF (0.55, normal value in serum and CSF< 0.22). After therapy (June 2011), antibody 
levels had dropped to 0.09 in serum (a lumbar puncture was not repeated after therapy). 
Seizures discontinued and anticonvulsive treatment was slowly tapered.  
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Discussion: 
Sparganosis is a rare parasitic disease caused by infestation with the larval cestode of 
Spirometra spp. Most cases have been reported in Southeast and Eastern Asia. Humans are 
infected through drinking unfiltered contaminated water or through consumption of raw 
snakes and frogs. When the parasite invades the central nervous system, epileptic seizures and 
headache are common symptoms [2]. Characteristic MRI findings of cerebral sparganosis 
include a ‘tunnel sign’, and ‘wandering lesions’ on successive images representing the track 
of motion of the parasite [6-7]. 
 
The treatment of choice for cerebral sparganosis is surgical removal because treatment with 
antihelmintics, including praziquantel, has been described as not effective [1-3]. In our patient 
the clinical improvement, and the normalisation of brain imaging and of anti-sparganum 
antibody levels suggest that the parasite was eradicated by high dose praziquantel therapy. 
Although the close temporal correlation of therapy and presumed death of the parasite 
suggests a causal relationship we cannot rule out the possibility that this was, in fact, due to a 
coinciding, natural death of the parasite and not due to the chemotherapeutics. There is no 
information regarding the cestode’s life expectancy in human tissue in the literature. 
 
Cerebral sparganosis should be suspected in patients from endemic areas with indications of 
cerebral parasitic infection and “wandering lesions” in the MRI. High-dose praziquantel 
treatment may be considered in inoperable cases of cerebral sparganosis. Ethylcholine PET 
can be used preoperatively for the precise localization of the sparganum. This should be 
particularly valuable if the precise location is not known due to the often multifocal lesions in 
MRI.  
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Figure Legend  
Radiology findings. The upper and middle row show axial brain MRIs in chronological order. 
The upper row shows contrast-enhanced horizontal T1-weighted sections (A - F). The middle 
row shows the corresponding T2 sections (G - L). Characteristic punctate calcifications in the 
CT in the affected region are shown in M. Repeated ethylcholine PET scans before and 3 and 
11 months after praziquantel therapy are shown in N, O, and P. The relative amount of tracer 
uptake is color-coded with arbitrary units. 
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